NCT05783466RecruitingNot Applicable
Bioactive Dairy Lipids to Manage Cardiometabolic Risk in Obesity
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Hospices Civils de Lyon
- Enrollment
- 75
- Locations
- 2
- Primary Endpoint
- Total plasma apolipoprotein B concentration
Study Overview
Brief Summary
It is a randomized parallel arm intervention study in adults with severe obesity. The objective is to demonstrate that within a dietary handling for weight loss, the daily ingestion during 3 months of whole dairy products enriched with milk polar lipids or whole dairy products decreases to a greater extent fasting plasma apolipoprotein B concentrations than the daily ingestion of low-fat dairy products (control group).
Metabolic parameters will be assessed before and after the 3-month intervention, both at fasting and in postprandial period after the consumption of standardized meals.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Other
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Men and women between 18-70 years
- •Body Mass Index (BMI) between 35 and 60 kg/m2 inclusive
- •Stable body weight (weight change +/- 5 % for 3 months prior to screening)
- •Consumption of at least 1 serving/day of dairy products made from cow's milk
- •Informed consent
Exclusion Criteria
- •History of bariatric or digestive surgery or disease interfering with main outcomes
- •Drinking more than 3 glasses of alcohol per day (>30g/day)
- •Pregnancy, parturiency or breastfeeding
- •Food allergies or intolerance to dairy products
- •Dietary restriction (vegetarian or lactovegetarian) or high protein diet
- •Use of dietary supplements
- •Treated with lipid lowering drugs (fibrates, statins, anti-PCSK9, ezetimibe, cholestyramine) within the last 6 weeks before study entry
- •Treated with insulin, GLP-1 analogs, acarbose, corticoids, beta-blockers.
- •Medications interfering with intestinal microbiota (beta-lactamines within 3 months before the study or laxatives)
- •Smoking ≥ 5 cigarettes/day during the past 6 months.
Arms & Interventions
Low-fat dairy products within a dietary handling for weight loss
Other
3 servings/day of low-fat dairy products: 1 serving of low-fat cheese, 1 serving of low-fat yogurt and 1 serving of (semi-)skimmed milk.
Intervention: Low-fat dairy products (Other)
Whole-fat dairy products within a dietary handling for weight loss
Experimental
3 servings/day of whole-fat dairy products: 1 serving of whole cheese, 1 serving of whole yogurt and 1 serving of whole milk.
Intervention: Whole-fat dairy products (Other)
Whole-fat dairy products enriched with milk polar lipids within a dietary handling for weight loss
Experimental
3 servings/day of whole-fat dairy products (1 milk, 1 yogurt, 1 cheese) among which 1 serving/day is enriched with milk polar lipids via butterier.
Intervention: Milk polar lipid enriched whole-fat dairy products (Other)
Outcomes
Primary Outcomes
Total plasma apolipoprotein B concentration
Time Frame: day 0 and day 90
Change in fasting total plasma apolipoprotein B concentration after 3-month intervention, measured by ELISA.
Secondary Outcomes
- Questionnaires on digestive comfort(day 0 and day 90)
- Anthropometric measurements 2(day 0 and day 90)
- Changes in weight(day 0 and day 90)
- Body mass composition measurements(day 0 and day 90)
- Plasma lipid concentrations after 3-month intervention, measured using standard laboratory methods 3(day 0 and day 90 for fasting and postprandial measurements. For postprandial measurements: time 360 minutes.)
- Plasma lipid concentrations after 3-month intervention, measured using standard laboratory methods 4(day 0 and day 90 for fasting and postprandial measurements. For postprandial measurements: time 360 minutes.)
- Glucose concentrations after 3-month intervention, measured using standard laboratory methods(day 0 and day 90 for fasting and postprandial measurements. For postprandial measurements: times 120 minutes -240 minutes)
- Glucose concentrations after 3-month intervention, measured using standard laboratory methods 2(day 0 and day 90 for fasting and postprandial measurements. For postprandial measurements: times 120 minutes -240 minutes)
- Plasma lipid concentrations after 3-month intervention, measured using standard laboratory methods(day 0 and day 90 for fasting and postprandial measurements. • For postprandial measurements: times 60 minutes-120 minutes -180 minutes -240 minutes -270 minutes -300 minutes -360 minutes)
- Targeted plasma lipidomics after 3-month intervention 4(day 0 and day 90 for fasting and postprandial measurements For postprandial measurements :times 120 minutes -240 minutes -300 minutes -360 minutes.)
- Targeted chylomicrons of plasma after 3-month intervention(day 0 and day 90 for fasting and postprandial measurements For postprandial measurements :times 120 minutes -240 minutes -300 minutes -360 minutes.)
- Targeted chylomicrons of plasma after 3-month intervention 2(day 0 and day 90 for fasting and postprandial measurements For postprandial measurements :times 120 minutes -240 minutes -300 minutes -360 minutes.)
- Targeted chylomicrons of plasma after 3-month intervention 3(day 0 and day 90 for fasting and postprandial measurements For postprandial measurements :times 120 minutes -240 minutes -300 minutes -360 minutes.)
- Targeted chylomicrons of plasma after 3-month intervention 4(day 0 and day 90 for fasting and postprandial measurements For postprandial measurements :times 120 minutes -240 minutes -300 minutes -360 minutes.)
- Inflammation markers(day 0 and day 90 for fasting and postprandial measurements.)
- Inflammation markers 5(day 0 and day 90 for fasting and postprandial measurements.)
- Inflammation markers 6(day 0 and day 90 for fasting and postprandial measurements.)
- Plasma lipid concentrations after 3-month intervention, measured using standard laboratory methods 7(day 0 and day 90 for fasting and postprandial measurements. For postprandial measurements:times 360 minutes.)
- Inflammation markers 4(day 0 and day 90 for fasting and postprandial measurements.)
- Inflammation markers 7(day 0 and day 90 for fasting and postprandial measurements.)
- Platelet activation markers(day 0 and day 90 for fasting and postprandial measurements. For postprandial measurements,times 120 minutes-240 minutes-300 minutes -360 minutes.)
- Oxidative stress marker(day 0 and day 90)
- Markers of immune cells 2(day 0 and day 90)
- Intestinal microbiota after 3-month intervention.(day 0 and day 90)
- Intestinal microbiota after 3-month intervention 2(day 0 and day 90)
- Plasma lipid concentrations after 3-month intervention, measured using standard laboratory methods 2(day 0 and day 90 for fasting and postprandial measurements. For postprandial measurements: times 120 minutes -180 minutes -240 minutes -270 minutes -300 minutes.)
- Plasma lipid concentrations after 3-month intervention, measured using standard laboratory methods 5(day 0 and day 90 for fasting and postprandial measurements. For postprandial measurements: times 120 minutes -240 minutes -300 minutes.)
- Plasma lipid concentrations after 3-month intervention, measured using standard laboratory methods 6(day 0 and day 90 for fasting and postprandial measurements. For postprandial measurements: times 120 minutes -240 minutes -300 minutes - 360 minutes)
- Plasma lipid concentrations after 3-month intervention, measured using standard laboratory methods 8(day 0 and day 90 for fasting and postprandial measurements. For postprandial measurements: times 120 minutes -240 minutes)
- Targeted plasma lipidomics after 3-month intervention 2(day 0 and day 90 for fasting and postprandial measurements For postprandial measurements :times 120 minutes -240 minutes -300 minutes -360 minutes.)
- Targeted plasma lipidomics after 3-month intervention 3(day 0 and day 90 for fasting and postprandial measurements For postprandial measurements :times 120 minutes -240 minutes -300 minutes -360 minutes.)
- Inflammation markers 3(day 0 and day 90 for fasting and postprandial measurements.)
- Markers of immune cells(day 0 and day 90)
- Targeted plasma lipidomics after 3-month intervention(day 0 and day 90 for fasting and postprandial measurements For postprandial measurements :times 120 minutes -240 minutes -300 minutes -360 minutes.)
- Questionnaires on physical activity(day 0 and day 90)
- Questionnaires on product satiety(day 0 and day 90)
- Targeted plasma lipidomics after 3-month intervention 5(day 0 and day 90 for fasting and postprandial measurements For postprandial measurements :times 120 minutes -240 minutes -300 minutes -360 minutes.)
- Inflammation markers 2(day 0 and day 90 for fasting and postprandial measurements.)
- Questionnaires on product appreciation(day 0 and day 90)
- Questionnaires food intake(day 0 and day 90)
- Dietary intake questionnaire(day 0 and day 90)
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Not Applicable
Dairy Attenuation of Metabolic DiseaseOxidative StressInflammationNCT01266330University of Tennessee40
Completed
Not Applicable
Dietary Approaches for Cardiometabolic HealthBlood PressureObesity, AbdominalWeight LossDyslipidemiasInsulin ResistanceNCT03527290University of California, Irvine30
Completed
Not Applicable
Effect of Conjugated Linoleic Acid Supplement on Body CompositionObesityNCT00347373University of North Carolina60
Completed
Not Applicable
Liver Fat as a Dietary Target for Treating Cardiometabolic Disorders in Prediabetes and Type 2 DiabetesNAFLDDiabetes Mellitus, Type 2PreDiabetesNCT04527965Uppsala University150
Recruiting
Not Applicable
Multiple Risk Factor Intervention Trial in Breast Cancer SurvivorsSedentary BehaviorBreast Cancer FemaleMetabolic DisturbanceNCT06454864University of Toronto45